CLINICAL IMMUNOLOGY
Immune recovery and the risk of CMV/ EBV reactivation in children post allogeneic haematopoietic stem cell transplantation
Submission date: 2016-05-18
Acceptance date: 2016-07-27
Publication date: 2016-10-25
Cent Eur J Immunol 2016;41(3):287-296
KEYWORDS
ABSTRACT
Immune reconstitution was studied prospectively in 86 children who underwent allogeneic haematopoietic stem cell transplantation (HSCT). We analysed the risk of cytomegalovirus (CMV) and Epstein-Barr virus (EBV) reactivation in correlation with the kinetics of immune recovery and in relation to other potential risk factors that may influence the reactivation of these viruses including: diagnosis, type of HSCT, source of stem cells, type of conditioning, or the occurrence of graft-versus-host disease (GvHD). The absolute number of lymphocyte subpopulations in peripheral blood was evaluated in seven timepoints following HSCT. Significantly lower values of both CD3+ and CD3+CD8+ lymphocytes on day +14 and significantly higher values of both these subsets on day +168 post-transplant in patients with CMV reactivation were observed. Significantly lower values of CD3+CD4+ subpopulation were noted in patients with CMV reactivation on day +28 post allo-HSCT. Significantly lower lymphocyte values in the group with EBV reactivation comparing with the group without EBV reactivation were confirmed only in the case of pan-B lymphocytes (CD19+) subpopulation on day +21, +28, and +84 post allo-HSCT. We identified the impact of CMV reactivation on occurrence of the intestinal acute GvHD, which occurred more frequently in the group with CMV reactivation compared with patients without reactivation. Higher incidence of chronic GvHD was also observed in patients with CMV reactivation compared to the group without reactivation. EBV reactivation occurred more frequently in patients receiving transplants from matched unrelated donors, in particular after peripheral blood stem cell transplantation and while implementing antithymocyte globulin as GvHD prophylaxis.
REFERENCES (26)
1.
Gratwohl A, Brand R, Frassoni F, et al. (2005): Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time. Bone Marrow Transplant 36: 757-769.
2.
Buhlmann LS, Buser AS, Cantoni N, et al. (2011): Lymphocyte subset recovery and outcome after T-cell replete allogeneic haematopoietic SCT. Bone Marrow Transplant 46: 1357-1362.
3.
Kałwak K, Gorczyńska E, Toporski J, et al. (2002): Immune reconstitution after haematopoietic cell transplantation in children: immunophenotype analysis with regard to factors affecting the speed of recovery. Br J Haematol 118: 74-89.
4.
Kałwak K, Porwolik J, Mielcarek M, et al. (2010): Higher CD34(+) and CD3(+) cell doses in the graft promote long-term survival, and have no impact on the incidence of severe acute or chronic graft-versus-host disease after in vivo T cell-depleted unrelated donor haematopoietic stem cell transplantation in children. Biol Blood Marrow Transplant 16: 388-401.
5.
Kim DH, Kim JG, Sohn SK, et al. (2004): Clinical impact of early absolute lymphocyte count after allogeneic stem cell transplantation. Br J Haematol 125: 217-224.
6.
Keever CA, Small TN, Flomenberg N, et al. (1989): Immune reconstitution following bone marrow transplantation: comparison of recipients of t-cell depleted marrow with recipients of conventional marrow grafts. Blood 73: 1340-1350.
7.
Wingard JR (1999): Opportunistic infections after blood and marrow transplantation. Transpl Infect Dis 1: 3-20.
8.
Kim SY, Lee DG, Kim MS, et al. (2008): The influence of infection early after allogeneic stem cell transplantation on the risk of leukemic relapse and graft-versus-host disease. Am J Hematol 83: 784-788.
9.
Boeckh M, Nichols WG, Papanicolaou G, et al. (2003): Cytomegalovirus in haematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies. Biol Blood Marrow Transplant 9: 543-558.
10.
Ljungman P, Griffiths P, Paya C (2002): Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 34: 1094-1097.
11.
Styczynski J, Einsele H, Gil L, Ljungman P (2009): Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in haematopoietic stem cell recipients: a comprehensive review of reported cases. Transpl Infect Dis 11: 383-392.
12.
Ocheni S, Kroeger N, Zabelina T, et al. (2008): EBV reactivation and post transplant lymphoproliferative disorders following allogeneic SCT. Bone Marrow Transplant 42: 181-186.
13.
Micallef IN, Chhanabhai M, Gascoyne RD, et al. (1998): Lymphoproliferative disorders following allogeneic bone marrow transplantation: the Vancouver experience. Bone Marrow Transplant 22: 981-987.
14.
Faye A, Vilmer E (2005): Post-transplant lymphoproliferative disorder in children: incidence, prognosis, and treatment options. Paediatr Drugs 7: 55-65.
15.
Styczynski J, Reusser P, Einsele H, et al. (2009): Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia. Bone Marrow Transplant 43: 757-770.
16.
Faraci M, Caviglia I,Morreale G, et al. (2010): Viral-load and B-lymphocyte monitoring of EBV reactivation after allogeneic hemopoietic SCT in children. Bone Marrow Transplant 45: 1052-1055.
17.
Masjosthusmann K, Ehlert K, Eing BR, et al. (2009): Delay in B-lymphocyte recovery and function following rituximab for EBV-associated lymphoproliferative disease early post-allogeneic haematopoietic SCT. Bone Marrow Transplant 43: 679-684.
18.
Gärtner BC, Schäfer H, Marggraff K, et al. (2002): Evaluation of use of Epstein-Barr viral load in patients after allogeneic stem cell transplantation to diagnose and monitor posttransplant lymphoproliferative disease. J Clin Microbiol 40: 351-358.
19.
Bacigalupo A, Ballen K, Rizzo D, et al. (2010): Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transpl 15: 1628-1633.
20.
Lugthart G, van Ostaijen-Ten Dam MM, Jol-van der Zijde CM, et al. (2014): Early cytomegalovirus reactivation leaves a specific and dynamic imprint on the reconstituting T cell compartment long-term after haematopoietic stem cell transplantation. Biol Blood Marrow Transplant 20: 655-661.
21.
Würsch AM, Gratama JW, Middeldorp JM, et al. (1985): The effect of cytomegalovirus infection on T lymphocytes after allogeneic bone marrow transplantation. Clin Exp Immunol 62: 278-287.
22.
Anderson AE, Lorenzi AR, Pratt A, et al. (2012): Immunity 12 years after alemtuzumab in RA: CD5B-cell depletion, thymus-dependent T-cell reconstitution and normal vaccine responses. Rheumatology (Oxford) 51: 1397-1406.
23.
Styczynski J, Reusser P, Einsele H, et al. (2008): Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia. Bone Marrow Transplant 43: 757-770.
24.
Gil L, Styczyński J, Komarnicki M, et al. (2012): Strategy of pre-emptive management of Epstein-Barr virus post-transplant lymphoproliferative disorder after stem cell transplantation: results of European transplant centers survey. Contemp Oncol (Pozn) 16: 338-340.
25.
Styczynski J, Gil L, Tridello G, et al. (2013): Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after haematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Clin Infect Dis 57: 794-802.
26.
Styczynski J, Tridello G, Gil L, et al. (2016). Impact of donor epstein-barr virus serostatus on the incidence of graft-versus-host disease in patients with acute leukemia after haematopoietic stem-cell transplantation: a study from the acute leukemia and infectious diseases working parties of the European Society for Blood and Marrow Transplantation. J Clin Oncol 34: 2212-2220.
Share
RELATED ARTICLE
| eISSN: | 1644-4124 |
| ISSN: | 1426-3912 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
